A clinical trial to study the effect of doxycycline in patients of chronic obstructive pulmonary disease with stable symptoms

Study of efficacy of of 4-weeks doxycycline in patients of moderate to severe chronic obstructive pulmonary disease with stable symptoms-a randomized, open-labeled, pilot trial

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/091/000042

Enrollment

Registered

2011-01-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic obstructive pulmonary disease

Interventions

Intervention1: Doxycycline: Doxycycline 100 mg OD for 4 weeks, Deriphylline 100 mg TDS Control Intervention1: Deriphylline: Deriphylline 100 mg TDS 4 weeks

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age > 40 years 2. Smoking history >10 packs years 3. Patients classified as GOLD criteria II and III 4. Ability to perform Pulmonary function tests

Exclusion criteria

Exclusion criteria: 1. Patient with acute exacerbation (Anthonisen et al) / critically ill patients 2. Patient with moderate/severe exacerbation in last 4 weeks as defined by severity scale proposed by Cazzola et al. 3. Patient with active respiratory disease other than COPD (tuberculosis, lung malignancies, Bronchiectasis, pneumonia, bronchial asthma) 4. Patient with acute systemic/local infection 5. Patient with cardiac disease (CCF, Recent myocardial infarction, Cardiac arrhythmias) 6. Patient with gastrointestinal disorders (Gastro-esophageal reflux disorder, peptic ulcer, Undiagnosed abdominal pain) 7. Patient with renal or hepatic impairment 8. Patient with h/o hypersensitivity to tetracyclines 9. Patient receiving oral corticosteroids

Design outcomes

Primary

Measure	Time frame
Change in post-bronchodilator Forced expiratory volume in one second (FEV1), Time point: 4 weeksTimepoint:	—

Secondary

Measure	Time frame
1. Change in mean FEV1 % predicted, Time point: 4 weeks 2. Change in mean Forced Vital Capacity (FVC) , Time point: 4 weeks 3. Change in mean FVC % predicted, Time point: 4 weeks 4. Change in Serum C-Reactive Protein, Time point: 4 weeks 5. Change in Medical Research Council Dyspnea Scale, Time point: 4 weeks Timepoint:	—

Countries

India

Contacts

Public ContactDr Prashant S. Dalvi

pwaves30@yahoo.co.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026